Summit Therapeutics Inc (SMMT)
RedHealth Care · As of 17 July 2026
Price chart — 52 weeks
OakBag could not build a reliable fair-value estimate for Summit Therapeutics Inc (SMMT) — none of its valuation methods cleared the model's safety checks (typically a company running an operating loss, where a discount can't be trusted). At a recent price of $13.81 the traffic light is set so it looks expensive or risky, benchmarked against other Health Care names. This is a model output for research, not a price target or a recommendation.
Fair value vs. price
- Current price
- $13.81
- Estimated fair value
- —
- Margin of safety
- —
How the fair value is built
—
Knock-out safety checks failed
- Bankruptcy risk (Altman Z″)
- Negative equity
- Excessive leverage
- Illiquid
- Penny / micro-cap
- Stale fundamentals
- Piotroski F-score
- 1 / 9
- Altman Z-score
- -0.57
- Beneish M-score
- -7.86
Quality & factor profile
See the full analysis
Create a free OakBag account to unlock every valuation method, price history, watchlists and email alerts for SMMT and 1,850+ other stocks.
No credit card · just an email
Frequently asked questions
Is Summit Therapeutics (SMMT) undervalued?
OakBag could not build a reliable fair-value estimate for Summit Therapeutics Inc — none of its valuation methods cleared the model's safety checks, which usually happens for a company running an operating loss. At a recent price of $13.81 the model looks expensive or risky. This is a model output, not investment advice.
What is margin of safety?
Margin of safety is how far below the estimated fair value the price sits: (fair value − price) ÷ fair value. It cannot be shown here because no reliable fair-value estimate could be built for this stock.
Does a green verdict mean I should buy SMMT?
No. OakBag is an educational and research tool, not investment advice. The traffic light is an automated model output based on third-party data that may be delayed or inaccurate. Always do your own research.
Other Health Care stocks
An educational and research tool — not investment advice. OakBag is an educational and research tool, not investment advice. Scores and rankings are automated model outputs based on third-party data and may be inaccurate or delayed. Nothing here is a recommendation to buy or sell any security. Investing involves risk, including possible loss of principal.